pbc launch re-set near term focu
think ocaliva sale trend get back track help
share recov earn call today compani
describ market plan help reset ocaliva launch
safeti warn letter last year place dent refil rate updat fda
label releas two week ago get ocaliva launch back track
view limit reaction share think investor must look
script reacceler us think increas market
educ physician grow becom familiar ocaliva dose
patient monitor would expect begin see uptick growth
ocaliva think help share recov biggest
valu driver intercept nash phase data think
focu readout could also drive recoveri reiter
outperform think investor view stock show-m stori
time stock signific upsid nash success
like mean investor re-focu stori somewher
ep estim chang ep estim
vs previous due spend cut discuss
today earn call decreas ocaliva sale pbc
risk target price outperform rate includ lower
expect ocaliva sale addit post-market safeti event fda
commun pipelin delay failur particularli compani
valuat metric
number share
price month
 close
suiss seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis
biotechnolog compani focus
develop commerci therapeut liver diseas
lead product oca obetichol acid develop primari
biliari cirrhosi nash
profit tax
chang work capit
flow oper
free cash-flow firm
flow invest
cash-flow financ activ
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
scenario intercept repres
credit compani on-going phase trial nash continu
believ nash biggest valu driver compani
grey scenario intercept repres credit
compani on-going phase trial nash would
surpris trial outright failur believ
scenario reflect worst-cas valuat compani
 close
lower oca estim still think long-
term peak potenti pbc remain think
like re-invest period educ physician like
slow growth model growth sale growth
sale growth rate
respect label updat clearer instruct dose
pbc popul child pugh view pbc launch head
right direct toward get back track would expect educ
comfort around label howev take time compani announc today
increas salesforc comment call would expect
soft due season trend gener re-educ around label take
time compani note discontinu stabil
stock limit catalyst relat nash think stock
recov pbc script sale trend re-acceler
safeti announc last year think mani investor question
commerci viabil ocaliva pbc well safeti ocaliva nash
dose higher point think investor view nash pbc
show-m stori think label updat somewhat lift overhang
think share go much thought would due gener investor
skeptic view ocaliva pbc nash show stori
signific focu call revers cirrhot trial dose rational
would expect due potenti toler cirrhot patient
slightli differ liver architectur cholestat diseas like pbc though
agre tough popul dose think ration trial
reason result revers posit think dataset
could give prescrib confid dose popul gotten particular
attent oca label updat recent think intercept lead player
nash space data ahead competitor like
selonsertib gilead madrig pharm recent
compani mention price
